Compugen Stock

Compugen ROE

The Return on Equity (ROE) of Compugen (CGEN) as of Sep 4, 2026 is 34.40 %. In the previous year, Return on Equity (ROE) was -25.92 % — a change of -232.75% (higher).

ROE

34.40 %

YoY

-232.75%

Last updated:

In 2026, Compugen's return on equity (ROE) was 34.40 %, a -232.75% increase from the -25.92 % ROE in the previous year.

The Compugen ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-60.68 USD
Jan 1, 2019
-71.34 USD
Jan 1, 2020
-22.76 USD
Jan 1, 2021
-30.81 USD
Jan 1, 2022
-43.38 USD
Jan 1, 2023
-28.61 USD
Jan 1, 2024
-25.92 USD
Jan 1, 2025
34.40 USD
The Compugen ROE history
YEARROEYoY
34.40 %-232.75%
-25.92 %-9.41%
-28.61 %-34.05%
-43.38 %+40.78%
-30.81 %+35.38%
-22.76 %-68.10%
-71.34 %+17.56%
-60.68 %-52.04%
-126.52 %+155.07%
-49.60 %+121.15%
-22.43 %+114.25%
-10.47 %
Access this data via the Eulerpool API

Compugen Stock analysis

What does Compugen do? Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.

ROE Details

Decoding Compugen's Return on Equity (ROE)

Compugen's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Compugen's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Compugen's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Compugen’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Compugen stock

Return on Equity (ROE) of Compugen is 34.40 % in 2026.

Return on Equity (ROE) of Compugen changed from -25.92 % to 34.40 %, representing a -232.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Compugen since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Compugen with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Compugen

All Key Metrics — Compugen